Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10538336	
Filing Date		2005-06-10	
First Named Inventor	Johan	nnis F. R. Blacquiere, et al	
Art Unit		2655	
Examiner Name			
Attorney Docket Numb	er	NL021272	

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	ate	of cited Decument		Releva	Columns, nt Passaç s Appear		
	1	6243353	B1	2001-06	i-05	NOZAKI ET A	L				
	2	6212327	B1	2001-04	i-03	BERSTIS ET	AL				
	3	6344878	B1	2002-02	1-05	EMURA					
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
			er Code Date   Name of Patentee or Applicant   Rele				Pages.	Columns.	Lines who	200	
Examiner Initial*	No	Publication Number			tion				nt Passag Appear	es or Re	
		Publication Number			tion					ges or Re	
Initial*	No 1	Publication Number	Code <sup>1</sup>	Date		of cited Docu	iment	Figure	s Appear	ges or Re	
Initial*	No 1		Code <sup>1</sup>	Date	citatio	of cited Docu	please click the Ad	Figure	s Appear	ges or Re	
Initial*	No 1		Code <sup>1</sup>	Date plication	citatio	of cited Docu	please click the Ad	Figure:	Add	umns,Lin	evant

U.S.PATENTS

#### 

THOMSON FLEC

Date Considered

B1 2002-08-28

	3	EP0774868		B2	1997-05-21	THOMASON ELEC		
	4	EP0975163		A2	2000-01-26	TOSHIBA JP CO LTD		
	5	WO0225936		A2	2002-03-28	KPENV		
If you wisl	h to a	d additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add	_
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Ţ5	
	1							

\*EXAMINER: Initial if reference considered, whether or not clastion is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at were USPTO\_GOLY or MPEP 901.04. 2 Enter office that sewed the document, by the low-latter code (WIPO

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

See Kind Codes of USPTO Platent Documents at year USPTO\_COV or MEPP 20104. 2 Enter office that assed the document, by the No-latent code (WIPO Standard ST3.) 2 For Japanese patient documents, the includation of the year of the region of the Emperor among precised the sensal number of the platent concern. 4 Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST1.66 (possible. 2 Applicant is to place a check mark their if Employable symbols. 2 Applicant is to place a check mark their if Employable symbols. 2 Applicant is to place a check mark their if Employable symbols.

Examiner Signature

2 EP0774868

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10538336
Filing Date		2005-06-10
First Named Inventor	Joha	nnis F. R. Blacquiere, et al
Art Unit		2655
Examiner Name		
Attorney Docket Numb	er	NL021272

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Edward W. Goodman/	Date (YYYY-MM-DD)	2006-08-24
Name/Print	Edward W. Goodman	Registration Number	28613

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.